Drug-pricing woes put the hurt on pharma junk bonds

Pharma's bonds are underperforming the wider junk-debt gauge, Bloomberg reports, with those sold by companies including Valeant ($VRX) and Endo ($ENDP) missing the mark. And that's bad news for drugmakers such as Concordia and Sucampo, which are marketing more than $2 billion of loans to finance takeovers. More

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.